ReviewNature reviews. Clinical oncology2022
Systemic therapy for early-stage breast cancer: learning from the past to build the future.
Review in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.Acta oncologica (Stockholm, Sweden) · 2025Trial
- Predicting early-stage breast cancer disease-free survival and adjuvant therapy benefit from multimodal information using deep learning.NPJ breast cancer · 2026Article
- NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ERα.Annals of surgical oncology · 2026Article
- Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response.Nature biomedical engineering · 2026Article
- CNet-Cox for interpretable network biomarker discovery and survival risk scoring in precise breast cancer prognosis.NPJ digital medicine · 2026Article
- Bandgap-enabled ultrasound tissue marking by a biodegradable metastructured hydrogel implant.Science advances · 2026Article
- Antiproliferative Effect of 24-Deoxysericoside From Terminalia macroptera Guill. & Perr. (Combretaceae) Against Breast Carcinoma: In Vitro, Molecular Docking and ADME Assessment.Cancer reports (Hoboken, N.J.) · 2026Article
- Fe/Pharmaceutics · 2026Article
- Impact of Delaying Disease Recurrence on Economic Burden in Patients with HER2+ Early-Stage Breast Cancer (eBC).ClinicoEconomics and outcomes research : CEOR · 2026Article
- Advances in locoregional surgical treatment ofFrontiers in oncology · 2026Review
- De-escalation of axillary surgery after neoadjuvant therapy in breast cancer: long-term outcomes of sentinel lymph node biopsy alone versus complete axillary lymph node dissection.Therapeutic advances in medical oncology · 2026Article
- The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- MGAT4EP promotes tumor progression and serves as a prognostic marker for breast cancer.Cancer biology & therapy · 2025Article
- A computation-efficient network with feature aggregation for cancer subtype classification on histopathological images.Engineering applications of artificial intelligence · 2025Article
- Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer.Cell death & disease · 2025Article
- Trends in Surgical Treatment for cT4 Breast Cancer After Neoadjuvant Systemic Therapy: A Nationwide Study in The Netherlands.Annals of surgical oncology · 2025Article
- Article
- Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025Review
- Impact of neoadjuvant and adjuvant chemotherapy on breast cancer prognosis in a propensity score matched population.Scientific reports · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of breast cancer has improved dramatically over the past century, from a strictly surgical approach to a coordinated one, including local and systemic therapies. Systemic therapies for early-stage disease were initially tested against observation or placebo only in adjuvant trials. Subsequent clinical trials focusing on treatment 'fine-tuning' had a marked increase in cohort size, duration and costs, leading to a growing interest in the neoadjuvant setting in the past decade. Neoadjuvant trial designs have the advantages of enabling the direct evaluation of treatment effects on tumour diameter and offer unique translational research opportunities through the comparative analysis of tumour biology before, during and after treatment. Current technologies enabling the identification of better predictive biomarkers are shaping the new era of (neo)adjuvant trials. An urgent need exists to reinforce collaboration between the pharmaceutical industry and academia to share data and thus establish large databases of biomarker data coupled with patient outcomes that are easily accessible to the scientific community. In this Review, we summarize the evolution of (neo)adjuvant trials from the pre-genomic to the post-genomic era and provide critical insights into how neoadjuvant studies are currently designed, discussing the need for better end points and treatment strategies that are more personalized, including in the post-neoadjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.